Windlas Biotech Ltd
Windlas Biotech Ltd Share Price Today: Live Updates & Key Insights
Get insights on Windlas Biotech Ltd’s fundamentals, financials, shareholding, peer comparison, corporate actions & performance. Track key metrics, price trends & market sentiment for informed decisions. Explore all data at Motilal Oswal.
Windlas Biotech Ltd Share Price Chart
Windlas Biotech Ltd Fundamentals
Traded Volume: 36,533
Market Cap(Cr): 1,674
Avg Traded Price 800.79
1 Year return -14.31%
Upper Circuit 814.3
Lower Circuit 791
P/E TTM 25.00
P/B Ratio 32.00
Traded Value(Cr) 290.09
EPS TTM 32.120
Book value 32.120
Dividend 1.00%
Windlas Biotech Ltd Share Price Performance
Shows the percentage change in stock price over different time periods
This section highlights Windlas Biotech Ltd stock price performance across key timeframes, including 1-week, 1-month, 3-month, Year-To-Date (YTD), and 1-year returns. It provides insights into the Windlas Biotech Ltd share price history, short-term movements, long-term trends, and overall investor sentiment
1W -4.44%
1M -15.59%
3M -22.40%
1Y -14.31%
YTD -22.96%
Windlas Biotech Ltd Traded Volume Movement
Shows the trading volume over different time periods
This section highlights Windlas Biotech Ltd daily and average traded volumes, offering insights into investor activity and market liquidity. Higher volumes than average often indicate rising interest, news impact, or shifting market sentiment
Yesterday 45374.00
Day Before Yesterday 70251.00
1W Avg 61297.60
1M Avg 55059.90
3M Avg 41764.29
Windlas Biotech Ltd Technical Details
Windlas Biotech Ltd technical indicators, such as support and resistance levels and pivot points, are calculated based on historical price and volume trends. These metrics help traders anticipate possible price movements and make informed trading decisions.
Support 1 785
Support 2 776
Support 3 762
Pivot Point : 800
Resistance 1 809
Resistance 2 823
Resistance 3 832
Windlas Biotech Ltd Corporate Actions
Windlas Biotech Ltd corporate actions include dividends, bonus issues, stock splits, and key company updates that may affect share price and investor sentiment. This section provides timely details on past and upcoming actions, including ex-date, record date, and payout ratio - helping investors make informed decisions based on Windlas Biotech Ltd’s capital allocation strategies.
All
Ex-Date 21-Jul-2025 Type D Description 5.80/share@116.00% Record Date 21-Jul-2025 Ratio 116.00
Ex-Date 17-Sep-2024 Type D Description 5.50/share@110.00% Record Date 17-Sep-2024 Ratio 110.00
Ex-Date 05-Sep-2023 Type D Description 4.00/share@80.00% Record Date 05-Sep-2023 Ratio 80.00
Ex-Date 09-Sep-2022 Type D Description 3.50/share@70.00% Record Date 12-Sep-2022 Ratio 70.00
Dividends
Announcement Date 21-Jul-2025 Ex Dividend Date 21-Jul-2025 Dividend(%) 116
Announcement Date 17-Sep-2024 Ex Dividend Date 17-Sep-2024 Dividend(%) 110
Announcement Date 05-Sep-2023 Ex Dividend Date 05-Sep-2023 Dividend(%) 80
Announcement Date 09-Sep-2022 Ex Dividend Date 09-Sep-2022 Dividend(%) 70
Bonus
No Bonus has been declared by WINDLAS
Splits
No Split has been declared by WINDLAS
Others
Rights No Rights has been declared by WINDLAS
Windlas Biotech Ltd Peer Comparison
Shows key financial metrics for the company and its peers
This section compares Windlas Biotech Ltd with leading peers in the banking sector based on key metrics such as market capitalization, 1-year return, P/E (TTM), and PB ratio. It helps investors evaluate Windlas Biotech Ltd's relative performance and valuation against major competitors.
Stock Name Shukra Pharmaceuticals Ltd ₹40.89 (-1.99%) M. Cap (Cr) 17.90 1 Yr Return (%) +601.37% P/E (TTM) 149.73 PB Ratio 32.98
Stock Name Bliss GVS Pharma Ltd ₹159.79 (-1.30%) M. Cap (Cr) 16.89 1 Yr Return (%) +23.81% P/E (TTM) 15.41 PB Ratio 1.67
Stock Name Beta Drugs Ltd ₹1661.10 (+1.72%) M. Cap (Cr) 16.77 1 Yr Return (%) -12.04% P/E (TTM) 39.53 PB Ratio 9.27
Stock Name Windlas Biotech Ltd ₹794.05 (-1.27%) M. Cap (Cr) 16.74 1 Yr Return (%) -14.31% P/E (TTM) 24.72 PB Ratio 3.53
Stock Name Syncom Formulations (India) Ltd ₹15.87 (-0.81%) M. Cap (Cr) 14.92 1 Yr Return (%) -19.73% P/E (TTM) 23.64 PB Ratio 4.36
Stock Name Hester Biosciences Ltd ₹1671.80 (-1.39%) M. Cap (Cr) 14.22 1 Yr Return (%) -29.81% P/E (TTM) 32.44 PB Ratio 4.53
Stock Name Jagsonpal Pharmaceuticals Ltd ₹201.59 (-2.06%) M. Cap (Cr) 13.46 1 Yr Return (%) -14.96% P/E (TTM) 21.73 PB Ratio 6.83
Windlas Biotech Ltd Cash Flow
Cash flow data provides a view of how money is generated and spent by Windlas Biotech Ltd, across its operating activities, investing activities, and financing activities.
PARTICULARS Operating Activities Mar 2025 68.23 Mar 2024 108.91 Mar 2023 60.98 Mar 2022 9.00 Mar 2021 11.45
PARTICULARS Investing Activities Mar 2025 -74.06 Mar 2024 -92.07 Mar 2023 -14.11 Mar 2022 -154.31 Mar 2021 -20.19
PARTICULARS Financing Activities Mar 2025 1.01 Mar 2024 -15.29 Mar 2023 -43.74 Mar 2022 130.09 Mar 2021 0.78
PARTICULARS Net Cash Flow Mar 2025 -4.82 Mar 2024 1.56 Mar 2023 3.13 Mar 2022 -15.22 Mar 2021 -2.30
Windlas Biotech Ltd Shareholding Pattern
This shows the ownership breakdown of Windlas Biotech Ltd, highlighting participation from Foreign Institutional Investors (FII), Mutual Funds, Public, Other Institutions, and Promoters.
Promoter 61.99%
Public 25.48%
Other Institutions 5.05%
FII 1.11%
Mutual Funds 6.39%
About Windlas Biotech Ltd
Windlas Biotech Limited, formerly known as Windlas Biotech Private Limited was incorporated in 2001. The Company got convertedfrom a Private Limited to a Public Limited Company and the name of the Company was changed to `Windlas Biotech Limited'. A fresh Certificate of Incorporation dated April 15, 2021, granted by the Registrar of Companies, Uttarakhand at Dehradun.The Company is engaged in manufacturing and trading of pharmaceutical products. Their manufacturing plants are located at Dehradun in Uttarakhand. It has three distinct strategic business verticals (SBVs) mainly comprising of CDMO services and products; domestic trade generics and over-the-counter (OTC) brands; and exports.The Company commenced operations at Dehradun Plant -IV in 2010. It provides a comprehensive range of CDMO services ranging from product discovery, product development, licensing and commercial manufacturing of generic products, including complex generics, in compliance with current Good Manufacturing Practices (GMP) with a focus on improved safety, efficacy and cost. In addition to this, it sells its own branded products in the trade generics and OTC markets as well as export generic products to several countries. The company focused on developing and launching new complex generic products containing APIs which are difficult to handle or formulate. It needs pairing with a device to make a drug-device combo primarily in solid and liquid pharmaceutical dosage forms to provide specialized capabilities to customers especially for high potency, controlled substances and low-solubility products. Further, the development and manufacturing of complex generic products typically involves a higher degree of expertise/ trained manpower and utilizes higher overall process times. Its complex generic products portfolio primarily comprises fixed dosage combinations, fixed dosage plus modified release combinations, customized generics and chewable or dispersible. In 2020, the Company acquired the erstwhile associate -Windlas Healthcare.To conclude, the company has introduced high quality systems across its manufacturing facilities that cover the full product lifecycle from process innovation and R&D, through the stages of process development, manufacturing, sales, and supply chain, to the customer evaluation of products as well as management systems for ensuring consistent quality, efficacy, and safety of products. And hence forth, the company identifies and approves multiple vendors to source the raw materials pursuant to robust vendor assessment, in addition to the suppliers approved by its customers.In August 2021, the Company made an Initial Public Offer of 8,729,023 Equity Shares by raising capital from public aggregating to Rs 401.53 Crore, comprising a Fresh Issue of 3,586,956 Equity Shares aggregating to Rs 165 Crore and an Offer for Sale of 5,142,067 Equity Shares aggregating to Rs 236.53 Crore.Company expanded the manufacturing capacity of capsule & tablet from over 5 billion units to over 7 billion units by March, 2022. In FY 2023-24, it commissioned Plant-V used in injectable formulations. In 2024-25, it enhanced the production infrastructure with the commissioning of the Plant-2 extension facility. Further, it commenced the Further, it commenced the OSD (Oral Solid Dosages) capacity expansion at Plant 6 Unit .
Chairman & Independent Directo
Vivek Dhariwal
Registered office 40/1 Mohabewala Industrial, Area, Dehradun, Uttarakhand, 248110
FAX :91-135-6608000
Background
Incorporation Year 2001
Face Value ₹5.00
Market Lot 1
FAQs on Windlas Biotech Ltd
How to buy Windlas Biotech Ltd shares on NSE?
To buy Windlas Biotech Ltd shares in Motilal Oswal, you just need to open a demat account and get your KYC documents verified.
What is the Windlas Biotech Ltd share price today?
The Windlas Biotech Ltd share price on NSE is ₹794.05 today.
What is the market cap of Windlas Biotech Ltd on NSE?
The company has a market capitalization of ₹1673.64.
What is the PE & PB ratio of Windlas Biotech Ltd?
PE is 25 and PB is 32.
What is the 52 Week High and Low of Windlas Biotech Ltd shares?
Windlas Biotech Ltd stock price high: ₹1178.85 Windlas Biotech Ltd stock price low: ₹665.10.